Summary

An international study led by Canadian researchers proves that a minimally invasive heart bypass technique developed in Ottawa helps patients recover faster with less pain. By avoiding cutting the breastbone, the procedure offers identical long-term safety and effectiveness as traditional open-heart surgery, helping thousands return to daily life sooner.

Each year, thousands of Canadians undergo cardiac surgery, including roughly 15,000 to 20,000 coronary artery bypass grafting (CABG) procedures, making it one of the most vital major operations in modern medicine. For decades, standard bypass surgery has required a full median sternotomy: cracking open the chest by splitting the breastbone (sternum). While effective, this conventional approach is profoundly invasive, entails significant trauma, substantial pain, and a long recovery period.

Now, a landmark international study led by Canadian researchers offers compelling proof that a less painful, faster-healing alternative is just as effective and safe.

A Made-in-Canada Surgical Innovation

The multivessel minimally invasive coronary artery bypass grafting technique (known as MICS CABG) was pioneered right here in Canada at the University of Ottawa Heart Institute (UOHI). Led by Dr. Marc Ruel, principal investigator of the study, Endowed Chair and Director of Minimally Invasive Cardiac Research at UOHI, and Professor at the University of Ottawa, the technique avoids splitting the sternum entirely.

Instead, surgeons navigate through a small incision made between the patient’s ribs. By preserving the structural integrity of the chest wall, the procedure dramatically reduces surgical trauma while treating complex, multivessel coronary artery disease.

The Landmark MIST Trial

While minimally invasive bypass surgery has gained traction globally, high-grade evidence comparing it directly against traditional open-chest surgery was previously limited to observational or single-centre studies.

To bridge this gap, Ottawa researchers conceived, designed, and led the MIST Trial (Minimally Invasive versus STernotomy). Published in The Lancet, MIST represents the world’s first randomized controlled clinical trial evaluating MICS CABG against traditional sternotomy.

Watch Dr. Marc Ruel discuss the MIST Trial:

Key Details of the Trial

  • Global Collaboration: The trial enrolled 170 patients across seven medical centres in six countries including Canada, the United States, Germany, Japan, China, and India.
  • Complex Multi-Graft Care: Patients who had blockages in multiple heart blood vessels got an average of three bypass surgeries during their operation.
  • Randomized Evaluation: Patients were randomly assigned to receive either the Ottawa-developed minimally invasive approach or conventional open-heart sternotomy.

Promising Results for Patients

The findings from the MIST Trial provide strong evidence of the advantages offered by the minimally invasive approach:

  • Faster back-on-your-feet recovery: Just one month after surgery, patients who had the smaller incision were moving around and doing physical activities much better than those who had their breastbone cut.
  • Easier on the body: Patients who had the minimally invasive procedure needed fewer blood transfusions and were able to get off breathing machines sooner.
  • Just as safe and effective: After one year, both groups of patients had the exact same excellent long-term results—with zero deaths, zero strokes, and equal relief from chest pain.

“The message for patients is simple: in centres with experienced teams, minimally invasive bypass surgery is a safe option that helps people return to their daily lives sooner,“— George Wells, PhD, principal biostatistician of the MIST Trial, director and principal investigator of the Cardiovascular Research Methods Centre at the Ottawa Heart Institute, and professor in the School of Epidemiology and Public Health at the University of Ottawa Faculty of Medicine.

Transforming the Future of Cardiac Care

For the thousands of patients diagnosed with coronary artery disease each year, the message from the trial is clear: in centres with experienced surgical teams, minimally invasive bypass surgery allows individuals to return to their daily lives and families much sooner.

Beyond its immediate clinical impact, the trial marks a major milestone for Canadian medical innovation. By conceptualizing the technique and proving its efficacy through a global trial, Canadian researchers have laid the groundwork for expanded surgical training, broader international adoption, and a new standard of care in cardiovascular surgery.

Subscribe to The Health Insider for ongoing, evidence-based healthcare delivered right to your inbox.

~ Read more from The Health Insider ~


The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.

0 Shares:
You May Also Like